Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer
This study has been completed.
Study NCT01439191 Information provided by Shanghai CP Guojian Pharmaceutical Co.,Ltd.
First Received on September 21, 2011. No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Metastatic Breast Cancer
Additional conditions recognized in this trial
More general conditions related to this trial
Neoplasms by Site
Interventions listed in this trial
humanized anti-HER2 antibody
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Antineoplastic Agents, Phytogenic
Physiological Effects of Drugs
Sponsors listed in this trial
Shanghai CP Guojian Pharmaceutical Co.,Ltd.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers